Opko outlines $560M-$585M 2026 revenue guidance while planning MDX3001 clinical start by end of 2026 or early 2027

Trial StartMDX3001Neutral

AI Analysis

Opko provided 2026 revenue guidance of $560M-$585M and announced plans to initiate MDX3001 clinical development by end of 2026 or early 2027.

Guidance

$560M-$585M

Importance:5/10

Sentiment:

0.00

revenue guidanceclinical trial start2026 outlook

Related Companies

Read the original article

Published by Seeking Alpha Healthcare on July 28, 2026 1:29 AM